Bright Minds Biosciences (DRUG) Income from Continuing Operations (2023 - 2024)

Bright Minds Biosciences (DRUG) posted Income from Continuing Operations of 35513.28 for Q4 2024, down 78.87% on a QoQ basis from 168091.41 in Q2 2024, and up 102.87% year-over-year from 17505.39 in Q1 2024.

Bright Minds Biosciences (DRUG) Income from Continuing Operations (2023 - 2024) Analysis & Trends

Bright Minds Biosciences' Income from Continuing Operations history runs 2 years deep, the most recent figure standing at 35513.28 for Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -37.09 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 227.36 Mn
4 NuCana 279.75 Bn 279.75 Bn - -3.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -26.94 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 362.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - -453.82 Mn
10 Bright Minds Biosciences 498.53 Mn 498.53 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 35,513.28
Jun 30, 2024 168,091.41
Dec 31, 2023 -1.24 Mn
Jun 30, 2023 -1.09 Mn